SUNDAY, JULY 15, 2018

NewLink Genetics and Merck accept vaccine industry awards

NewLink Genetics and Merck & Co accept excellence awards
NewLink Genetics and Merck & Co accept excellence awards | Courtesy of
NewLink Genetics Corp., a biopharmaceutical company that makes innovative immunotherapeutic medicines available to cancer patients around the world, and Merck & Co. Inc. recently accepted Vaccine Industry Excellence (ViE) awards in the categories of “Best Vaccine License” and “Best Prophylactic Vaccine.”

"We appreciate the World Vaccine Congress' recognition of NewLink Genetics' leadership and innovation in advancing critical vaccines such as rVSV-EBOV for Ebola and other difficult global infectious diseases," NewLink CEO and Chairman Charles Link said. "With NewLink Genetics' and Merck's combined expertise and commitment to vaccine development, we see great promise in our ability to deliver novel treatment options for these important global health concerns."

The ViE Awards recognize the accomplishments, efforts and positive contributions that individuals and companies make in the vaccine industry.

"We are delighted to see our collaboration with NewLink receive this level of recognition from our industry colleagues," Mark Feinberg, chief public health and science officer for Merck Vaccines, said. "These awards also recognize the close working relationship we have established in developing our rVSV-ZEBOV vaccine candidate."

The two companies received the awards at the 15th Annual World Vaccine Congress in Washington, D.C., on April 8.

Organizations in this Story

NewLink Genetics Corporation

Want to get notified whenever we write about NewLink Genetics Corporation ?
Next time we write about NewLink Genetics Corporation, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.